Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial

By sjmartinez • December 17, 2023

Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer. 2023 Dec 16;32(1):34. doi: 10.1007/s00520-023-08176-6. PMID: 38103088; PMCID: PMC10725375.

Tags: breast cancer, Docetaxel /doxorubicin therapy, Efbemalenograstim alfa, Febrile neutropenia, Fusion protein, Granulocyte-colony stimulating factor, Hematology/Oncology, Publications

Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics

Rodriguez GE, Zhao Y, Nishiga Y, Peprah F, Shen J, Abhiraman GC, Ogishi M, Zhang C, Saco J, Waghray D, Serasanambati M, Torres L, Simone[...]

Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases

Ni JR, Quirk M, Chmielowski B, Padia SA. Yttrium-90 Radioembolization as a Safe and Effective Treatment Option for Hepatic Uveal Melanoma Metastases. Cardiovasc Intervent Radiol.[...]

Advancements in intratumoral therapies for liver tumors

Raman SS, Cutler NR, Sramek JJ, Hecht JR, Finn RS, Anand SR, Chiang J, Lu DS. Advancements in intratumoral therapies for liver tumors. Front Oncol.[...]